Trump Endorses Medical Cannabis Benefits Following Rescheduling Move

Former President Donald Trump publicly endorsed the medical benefits of cannabis following recent federal rescheduling developments, marking a notable evolution in his stance on marijuana policy. The comments come as the cannabis industry navigates ongoing regulatory uncertainty while major operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) position themselves for potential federal reform.

Trump's endorsement carries weight given his influence within Republican circles and potential 2028 political ambitions. His shift toward supporting medical cannabis aligns with broader bipartisan momentum around marijuana reform, particularly as rescheduling moves through federal agencies. This political backing could accelerate legislative progress on banking reform and interstate commerce provisions that have constrained industry growth.

The timing proves critical for cannabis operators struggling with Section 280E tax burdens and limited access to traditional banking services. Multi-state operators have burned through cash while building infrastructure across fragmented state markets, with many trading at significant discounts to revenue multiples. Federal rescheduling would eliminate the 280E tax penalty that forces cannabis companies to pay effective tax rates exceeding 70% in some cases.

Industry analysts view political endorsements from both parties as essential for normalizing cannabis investment and attracting institutional capital. Major pension funds and institutional investors remain sidelined due to federal prohibition, limiting access to growth capital for expansion and consolidation. Trump's medical cannabis support could help bridge the gap with conservative investors who have avoided the sector despite strong state-level revenue growth.

The regulatory landscape continues evolving as more states launch adult-use programs and medical markets expand. Cannabis companies face the dual challenge of managing current operations under restrictive federal rules while preparing for potential regulatory changes that could reshape competitive dynamics. Political momentum from figures like Trump adds credibility to industry projections that federal reform will eventually unlock the sector's institutional investment potential and enable true national market development.